ACR Convergence 2024

November 14-19, 2024. Washington, DC.

View by Number View by Title View Sessions

Sunday, November 17, 2024

10:30AM-12:30PM: Abstract Number: 1026

Healthcare Utilization and Childhood Opportunity Index in Patients with Juvenile Idiopathic Arthritis and Systemic Lupus Erythematosus

Healthcare Disparities in Rheumatology Poster II

10:30AM-12:30PM: Abstract Number: 1343

Heightened Gout Risk in Patients with Rheumatoid Arthritis: A National Cohort Study

RA – Diagnosis, Manifestations, & Outcomes Poster II

10:30AM-12:30PM: Abstract Number: 1090

Hepatic Fibrosis Before and During Intensive Urate-lowering with Pegloticase in the Presence and Absence of Methotrexate Co-therapy

Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster II

10:30AM-12:30PM: Abstract Number: 1213

High Prevalence of and Medication Use in Musculoskeletal and Chronic Multisite Pain in Community-Dwelling Older Adults: The Framingham Heart Study

Pain in Rheumatic Disease Including Fibromyalgia Poster

10:30AM-12:30PM: Abstract Number: 1188

High Risk of Stroke in Men with Joint Prosthesis Due to Osteoarthritis: The Prospective STRAMBO Study

Osteoarthritis – Clinical Poster I

10:30AM-12:30PM: Abstract Number: 0905

High-Throughput Proteomic Profiling of Sera as a Non-Invasive Method for Identifying Lupus Nephritis Subtypes

Genetics, Genomics & Proteomics Poster

10:30AM-12:30PM: Abstract Number: 1256

Higher Disease Activity in Pediatric Systemic Lupus Erythematosus Is Associated with a Greater Desire for Social Health Education: An Unmet Need in Pediatric Rheumatology

Pediatric Rheumatology – Clinical Poster II

10:30AM-12:30PM: Abstract Number: 1493

How Do Lupus Nephritis Patients Who Achieve Renal Remission Fare? A 3-year Comparison in Terms of GFR Decline

SLE – Diagnosis, Manifestations, & Outcomes Poster II

10:30AM-12:30PM: Abstract Number: 0894

HOXD13 Regulation of Primary Cilia in Rheumatoid Arthritis Synovial Fibroblasts: Implications for Joint-Specific Pathogenesis

Genetics, Genomics & Proteomics Poster

10:30AM-12:30PM: Abstract Number: 1547

Hydroxychloroquine and Prednisone Use by Individuals Diagnosed with Systemic Lupus Erythematosus in the TriNetX Research Database

SLE – Treatment Poster II

10:30AM-12:30PM: Abstract Number: 0896

Identification of Immune Pathways Regulated by a Non-Coding Variant at DNASE1L3/PXK/PDHB

Genetics, Genomics & Proteomics Poster

10:30AM-12:30PM: Abstract Number: 0887

Identification of Rare Variants in Lupus-causing Genes in a Mixed Paediatric and Adult Connective Tissue Disease Cohort

Genetics, Genomics & Proteomics Poster

10:30AM-12:30PM: Abstract Number: 1042

Identifying Patient Priorities for Patient-Reported Outcome Measures in Rheumatoid Arthritis: A Modified Delphi Consensus Study

Health Services Research – ACR/ARP Poster II

10:30AM-12:30PM: Abstract Number: 0909

Identifying Predictive Serum Soluble Mediators Signatures Specific to ANA+ at Risk of SLE Individuals with Next Generation Proteomics

Genetics, Genomics & Proteomics Poster

10:30AM-12:30PM: Abstract Number: 1008

Immune Responses to Infection and Autoimmune Diseases in the UK Biobank

Epidemiology & Public Health Poster II

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].